Iranian Journal of Diabetes and Obesity
Shahid Sadoughi University Of Medical Sciences
Sat, Aug 22, 2026
[Archive]
Volume 18, Issue 3 (8-2026)
IJDO 2026, 18(3): 227-238 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Abbasi-Bafetrat A, Abbasi-Bafetrat M. Epigenetics in Diabetes Management: A Comprehensive Review of Diagnostic and Preventive Strategies. IJDO 2026; 18 (3) :227-238
URL: http://ijdo.ssu.ac.ir/article-1-1064-en.html
URL: http://ijdo.ssu.ac.ir/article-1-1064-en.html
Clinical Research Development Unit, Hajar Hospital, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Abstract: (26 Views)
As diabetes mellitus evolves into a global health crisis, conventional diagnostic and therapeutic paradigms are no longer sufficient and necessitate innovative treatment approaches that extend beyond traditional pharmacotherapy. Recent advances in epigenetics have uncovered heritable and reversible changes in gene regulation that contribute to the pathogenesis of diabetes.
This review provides a comprehensive analysis of various epigenetic mechanisms, including DNA methylation, histone modifications, and the role of non-coding RNAs in diabetes development, and evaluates their integration into a precision medicine framework for early diagnosis, risk stratification, and biomarker-guided therapeutic interventions. Furthermore, we discuss personalized management strategies that leverage epigenetic understanding to optimize therapeutic and preventive outcomes. Finally, we consider the upcoming obstacles and prospective scope of personalized medicine in the field of diabetes management. Incorporating epigenetic profiling into diagnostic and therapeutic workflows enables higher-resolution risk assessment, precision targeting of interventions, and improved pharmacodynamic outcomes. Epigenetically informed strategies, including HDAC inhibitors, DNMT modulators, and microbiota-driven interventions, hold promise for enhancing therapeutic efficacy, optimizing drug selection, and personalizing lifestyle interventions.
While translational challenges remain, this review highlights that the integration of epigenetic data with genomics, metabolomics, and microbiomics facilitates next-generation personalized diabetes care and has the potential to reshape both clinical practice and public health strategies in the fight against diabetes.
This review provides a comprehensive analysis of various epigenetic mechanisms, including DNA methylation, histone modifications, and the role of non-coding RNAs in diabetes development, and evaluates their integration into a precision medicine framework for early diagnosis, risk stratification, and biomarker-guided therapeutic interventions. Furthermore, we discuss personalized management strategies that leverage epigenetic understanding to optimize therapeutic and preventive outcomes. Finally, we consider the upcoming obstacles and prospective scope of personalized medicine in the field of diabetes management. Incorporating epigenetic profiling into diagnostic and therapeutic workflows enables higher-resolution risk assessment, precision targeting of interventions, and improved pharmacodynamic outcomes. Epigenetically informed strategies, including HDAC inhibitors, DNMT modulators, and microbiota-driven interventions, hold promise for enhancing therapeutic efficacy, optimizing drug selection, and personalizing lifestyle interventions.
While translational challenges remain, this review highlights that the integration of epigenetic data with genomics, metabolomics, and microbiomics facilitates next-generation personalized diabetes care and has the potential to reshape both clinical practice and public health strategies in the fight against diabetes.
Type of Study: Research |
Subject:
Special
Received: 2026/08/22 | Accepted: 2026/08/19 | Published: 2026/08/19
Received: 2026/08/22 | Accepted: 2026/08/19 | Published: 2026/08/19
References
1. Care D. Care in Diabetesd2021. Diabetes care. 2021;44(1):S152S33. [DOI:10.2337/dc21-ad09]
2. Magliano DJ, Boyko EJ. IDF diabetes atlas. 2022. https://www.ncbi.nlm.nih.gov/books/NBK581934/
3. Nathan DM. Diabetes: advances in diagnosis and treatment. Jama. 2015;314(10):1052-62. [DOI:10.1001/jama.2015.9536]
4. Liu J, Lang G, Shi J. Epigenetic regulation of PDX-1 in type 2 diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity. 2021:431-42. [DOI:10.2147/DMSO.S291932]
5. Wu YL, Lin ZJ, Li CC, Lin X, Shan SK, Guo B, et al. Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study. Signal Transduction and Targeted Therapy. 2023;8(1):98. [DOI:10.1038/s41392-023-01333-7]
6. Mittal R, Camick N, Lemos JR, Hirani K. Gene-environment interaction in the pathophysiology of type 1 diabetes. Frontiers in endocrinology. 2024;15:1335435. [DOI:10.3389/fendo.2024.1335435]
7. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: pathogenesis and treatment. The Lancet. 2008;371(9631):2153-6. [DOI:10.1016/S0140-6736(08)60932-0]
8. P Polychronakos C, Li Q. Understanding type 1 diabetes through genetics: advances and prospects. Nature Reviews Genetics. 2011;12(11):781-92. [DOI:10.1038/nrg3069]
9. Noble JA, Valdes AM. Genetics of the HLA region in the prediction of type 1 diabetes. Current diabetes reports. 2011;11(6):533-42. [DOI:10.1007/s11892-011-0223-x]
10. Sundaresan B, Shirafkan F, Ripperger K, Rattay K. The role of viral infections in the onset of autoimmune diseases. Viruses. 2023;15(3):782. [DOI:10.3390/v15030782]
11. Minniakhmetov I, Yalaev B, Khusainova R, Bondarenko E, Melnichenko G, Dedov I, et al. Genetic and epigenetic aspects of type 1 diabetes mellitus: modern view on the problem. Biomedicines. 2024;12(2):399. [DOI:10.3390/biomedicines12020399]
12. Kowluru RA, Mohammad G. Epigenetic modifications in diabetes. Metabolism. 2022;126:154920. [DOI:10.1016/j.metabol.2021.154920]
13. Lima JE, Moreira NC, Sakamoto-Hojo ET. Mechanisms underlying the pathophysiology of type 2 diabetes: From risk factors to oxidative stress, metabolic dysfunction, and hyperglycemia. Mutation Research/Genetic Toxicology and Environmental Mutagenesis. 2022;874:503437. [DOI:10.1016/j.mrgentox.2021.503437]
14. Chartrand DJ, Murphy-Despres A, Almeras N, Lemieux I, Larose E, Despres JP. Overweight, obesity, and CVD risk: a focus on visceral/ectopic fat. Current atherosclerosis reports. 2022;24(4):185-95. [DOI:10.1007/s11883-022-00996-x]
15. Ding Q, Gao Z, Chen K, Zhang Q, Hu S, Zhao L. Inflammation-related epigenetic modification: the bridge between immune and metabolism in type 2 diabetes. Frontiers in immunology. 2022;13:883410. [DOI:10.3389/fimmu.2022.883410]
16. Tong Y, Xu S, Huang L, Chen C. Obesity and insulin resistance: Pathophysiology and treatment. Drug Discovery Today. 2022;27(3):822-30. [DOI:10.1016/j.drudis.2021.11.001]
17. Ahmed B, Sultana R, Greene MW. Adipose tissue and insulin resistance in obese. Biomedicine & pharmacotherapy. 2021;137:111315. [DOI:10.1016/j.biopha.2021.111315]
18. Kirichenko TV, Markina YV, Bogatyreva AI, Tolstik TV, Varaeva YR, Starodubova AV. The role of adipokines in inflammatory mechanisms of obesity. International journal of molecular sciences. 2022;23(23):14982. [DOI:10.3390/ijms232314982]
19. Ling C, Bacos K, Rönn T. Epigenetics of type 2 diabetes mellitus and weight change-a tool for precision medicine?. Nature Reviews Endocrinology. 2022;18(7):433-48. [DOI:10.1038/s41574-022-00671-w]
20. Naidoo V, Naidoo M, Ghai M. Cell‐and tissue‐specific epigenetic changes associated with chronic inflammation in insulin resistance and type 2 diabetes mellitus. Scandinavian journal of immunology. 2018;88(6):e12723. [DOI:10.1111/sji.12723]
21. Bansal A, Pinney SE. DNA methylation and its role in the pathogenesis of diabetes. Pediatric diabetes. 2017;18(3):167-77. [DOI:10.1111/pedi.12521]
22. Davegårdh C, García-Calzón S, Bacos K, Ling C. DNA methylation in the pathogenesis of type 2 diabetes in humans. Molecular metabolism. 2018;14:12-25. [DOI:10.1016/j.molmet.2018.01.022]
23. Wang W, Shi Q, Guo T, Yang Z, Jia Z, Chen P, et al. PDX1 and ISL1 differentially coordinate with epigenetic modifications to regulate insulin gene expression in varied glucose concentrations. Molecular and cellular endocrinology. 2016 Jun 15;428:38-48. [DOI:10.1016/j.mce.2016.03.019]
24. Qie R, Han M, Huang S, Li Q, Liu L, Zhang D, et al. Association of TCF7L2 gene polymorphisms, methylation, and gene-environment interaction with type 2 diabetes mellitus risk: A nested case-control study in the Rural Chinese Cohort Study. Journal of Diabetes and its Complications. 2021;35(3):107829. [DOI:10.1016/j.jdiacomp.2020.107829]
25. Chen X, Ayala I, Shannon C, Fourcaudot M, Acharya NK, Jenkinson CP, et al. The diabetes gene and Wnt pathway effector TCF7L2 regulates adipocyte development and function. Diabetes. 2018;67(4):554-68. [DOI:10.2337/db17-0318]
26. van Otterdijk SD, Binder AM, Szarc vel Szic K, Schwald J, Michels KB. DNA methylation of candidate genes in peripheral blood from patients with type 2 diabetes or the metabolic syndrome. PLoS One. 2017;12(7):e0180955. [DOI:10.1371/journal.pone.0180955]
27. Zhu M, Huang Q, Li H, Zhao Y, Guo H, Wang T, et al. The impact of site-specific DNA methylation in KCNJ11 promoter on type 2 diabetes. Heliyon. 2024;10(22):e39934. [DOI:10.1016/j.heliyon.2024.e39934]
28. Samblas M, Milagro FI, Martínez A. DNA methylation markers in obesity, metabolic syndrome, and weight loss. Epigenetics. 2019;14(5):421-44. [DOI:10.1080/15592294.2019.1595297]
29. Sayols-Baixeras S, Subirana I, Fernández-Sanlés A, Sentí M, Lluís-Ganella C, Marrugat J, et al. DNA methylation and obesity traits: An epigenome-wide association study. The REGICOR study. Epigenetics. 2017;12(10):909-16. [DOI:10.1080/15592294.2017.1363951]
30. Nilsson E, Matte A, Perfilyev A, de Mello VD, Käkelä P, Pihlajamäki J, et al. Epigenetic alterations in human liver from subjects with type 2 diabetes in parallel with reduced folate levels. The Journal of Clinical Endocrinology & Metabolism. 2015;100(11):E1491-E501. [DOI:10.1210/jc.2015-3204]
31. Yadav DK, Shrestha S, Lillycrop KA, Joglekar CV, Pan H, Holbrook JD, et al. Vitamin B12 supplementation influences methylation of genes associated with Type 2 diabetes and its intermediate traits. Epigenomics. 2018;10(1):71-90. [DOI:10.2217/epi-2017-0102]
32. Maher A, Sobczyńska-Malefora A. The relationship between folate, vitamin B12 and gestational diabetes mellitus with proposed mechanisms and foetal implications. Journal of Family & Reproductive Health. 2021;15(3):141. [DOI:10.18502/jfrh.v15i3.7131]
33. Prasad M, Rajagopal P, Devarajan N, Veeraraghavan VP, Palanisamy CP, Cui B, et al. A comprehensive review on high-fat diet-induced diabetes mellitus: an epigenetic view. The Journal of Nutritional Biochemistry. 2022;107:109037. [DOI:10.1016/j.jnutbio.2022.109037]
34. Zhang Y, Sun Z, Jia J, Du T, Zhang N, Tang Y, et al. Overview of histone modification. Histone Mutations and Cancer. 2021:1-16. [DOI:10.1007/978-981-15-8104-5_1]
35. Sharma S, Taliyan R. Histone deacetylase inhibitors: Future therapeutics for insulin resistance and type 2 diabetes. Pharmacological research. 2016;113:320-6. [DOI:10.1016/j.phrs.2016.09.009]
36. Bakhdar FA, Magadmi RM, El-Kordy EA, Alamri AS. Effect of histone deacetylase inhibitor (vorinostat) on new-onset diabetes induced by tacrolimus. Journal of Taibah University Medical Sciences. 2023;18(1):9-18. [DOI:10.1016/j.jtumed.2022.07.004]
37. Hadden MJ, Advani A. Histone deacetylase inhibitors and diabetic kidney disease. International journal of molecular sciences. 2018;19(9):2630. [DOI:10.3390/ijms19092630]
38. Dewanjee S, Vallamkondu J, Kalra RS, Chakraborty P, Gangopadhyay M, Sahu R, et al. The emerging role of HDACs: pathology and therapeutic targets in diabetes mellitus. Cells. 2021;10(6):1340. [DOI:10.3390/cells10061340]
39. Ramatchandirin B, Pearah A, He L. Regulation of liver glucose and lipid metabolism by transcriptional factors and coactivators. Life. 2023;13(2):515. [DOI:10.3390/life13020515]
40. Emamgholipour S, Ebrahimi R, Bahiraee A, Niazpour F, Meshkani R. Acetylation and insulin resistance: a focus on metabolic and mitogenic cascades of insulin signaling. Critical reviews in clinical laboratory sciences. 2020;57(3):196-214. [DOI:10.1080/10408363.2019.1699498]
41. Małodobra-Mazur M, Cierzniak A, Myszczyszyn A, Kaliszewski K, Dobosz T. Histone modifications influence the insulin-signaling genes and are related to insulin resistance in human adipocytes. The International Journal of Biochemistry & Cell Biology. 2021;137:106031. [DOI:10.1016/j.biocel.2021.106031]
42. Gupta P, Taiyab A, Hassan MI. Emerging role of protein kinases in diabetes mellitus: From mechanism to therapy. Advances in protein chemistry and structural biology. 2021;124:47-85. [DOI:10.1016/bs.apcsb.2020.11.001]
43. Li X, Lu L, Hou W, Huang T, Chen X, Qi J, et al. Epigenetics in the pathogenesis of diabetic nephropathy: Epigenetics in the pathogenesis of diabetic nephropathy. Acta Biochimica et Biophysica Sinica. 2021;54(2):163. [DOI:10.3724/abbs.2021016]
44. Li C, Ni Y-Q, Xu H, Xiang Q-Y, Zhao Y, Zhan J-K, et al. Roles and mechanisms of exosomal non-coding RNAs in human health and diseases. Signal transduction and targeted therapy. 2021;6(1):383. [DOI:10.1038/s41392-021-00779-x]
45. He X, Kuang G, Wu Y, Ou C. Emerging roles of exosomal miRNAs in diabetes mellitus. Clinical and translational medicine. 2021;11(6):e468. [DOI:10.1002/ctm2.468]
46. Mageed SSA, Doghish AS, Ismail A, El-Husseiny AA, Fawzi SF, Mahmoud AM, et al. The role of miRNAs in insulin resistance and diabetic macrovascular complications-A review. International journal of biological macromolecules. 2023;230:123189. [DOI:10.1016/j.ijbiomac.2023.123189]
47. Tello-Flores VA, Beltrán-Anaya FO, Ramírez-Vargas MA, Esteban-Casales BE, Navarro-Tito N, Alarcón-Romero LdC, et al. Role of long non-coding RNAs and the molecular mechanisms involved in insulin resistance. International Journal of Molecular Sciences. 2021;22(14):7256. [DOI:10.3390/ijms22147256]
48. Luo Y, Cui C, Han X, Wang Q, Zhang C. The role of miRNAs in polycystic ovary syndrome with insulin resistance. Journal of Assisted Reproduction and Genetics. 2021;38:289-304. [DOI:10.1007/s10815-020-02019-7]
49. Macvanin M, Obradovic M, Zafirovic S, Stanimirovic J, Isenovic ER. The role of miRNAs in metabolic diseases. Current Medicinal Chemistry. 2023;30(17):1922-44. [DOI:10.2174/0929867329666220801161536]
50. Bi Y, Wang Y, Sun X. Recent Advances of LncRNA H19 in Diabetes. Hormone and Metabolic Research. 2022;54(04):212-9. [DOI:10.1055/a-1769-5032]
51. Wu Q, Huang F. LncRNA H19: a novel player in the regulation of diabetic kidney disease. Frontiers in Endocrinology. 2023;14:1238981. [DOI:10.3389/fendo.2023.1238981]
52. Akil AA-S, Yassin E, Al-Maraghi A, Aliyev E, Al-Malki K, Fakhro KA. Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era. Journal of translational medicine. 2021;19(1):137. [DOI:10.1186/s12967-021-02778-6]
53. Shoily SS, Ahsan T, Fatema K, Sajib AA. Common genetic variants and pathways in diabetes and associated complications and vulnerability of populations with different ethnic origins. Scientific Reports. 2021;11(1):7504. [DOI:10.1038/s41598-021-86801-2]
54. Sugandh F, Chandio M, Raveena F, Kumar L, Karishma F, Khuwaja S, et al. Advances in the management of diabetes mellitus: a focus on personalized medicine. Cureus. 2023;15(8):e43697. [DOI:10.7759/cureus.43697]
55. DeForest N, Majithia AR. Genetics of type 2 diabetes: implications from large-scale studies. Current diabetes reports. 2022;22(5):227-35. [DOI:10.1007/s11892-022-01462-3]
56. Kulyté A, Aman A, Strawbridge RJ, Arner P, Dahlman IA. Genome-wide association study identifies genetic loci associated with fat cell number and overlap with genetic risk loci for type 2 diabetes. Diabetes. 2022;71(6):1350-62. [DOI:10.2337/db21-0804]
57. Giglio RV, Stoian AP, Patti AM, Rizvi AA, Sukhorukov V, Ciaccio M, et al. Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of metabolic syndrome. Current Pharmaceutical Design. 2021;27(35):3729-40. [DOI:10.2174/1381612827666210412145915]
58. Klimczak S, Śliwińska A, editors. Epigenetic regulation of inflammation in insulin resistance. Seminars in Cell & Developmental Biology; 2024:15;154(Pt C):185-192. [DOI:10.1016/j.semcdb.2022.09.004]
59. Venkatachalapathy P, Padhilahouse S, Sellappan M, Subramanian T, Kurian SJ, Miraj SS, et al. Pharmacogenomics and personalized medicine in type 2 diabetes mellitus: potential implications for clinical practice. Pharmacogenomics and Personalized Medicine. 2021:1441-55. [DOI:10.2147/PGPM.S329787]
60. Kenanoglu S, Gokce N, Akalin H, Ergoren MC, Beccari T, Bertelli M, et al. Implication of the Mediterranean diet on the human epigenome. Journal of preventive medicine and hygiene. 2022;63(2 Suppl 3):E44-E55.
61. Plaza-Diaz J, Izquierdo D, Torres-Martos Á, Baig AT, Aguilera CM, Ruiz-Ojeda FJ. Impact of physical activity and exercise on the epigenome in skeletal muscle and effects on systemic metabolism. Biomedicines. 2022;10(1):126. [DOI:10.3390/biomedicines10010126]
62. Odimegwu CL, Uwaezuoke SN, Chikani UN, Mbanefo NR, Adiele KD, Nwolisa CE, et al. Targeting the Epigenetic Marks in Type 2 Diabetes Mellitus: Will Epigenetic Therapy Be a Valuable Adjunct to Pharmacotherapy? Diabetes, Metabolic Syndrome and Obesity. 2024:3557-76. [DOI:10.2147/DMSO.S479077]
63. Natarajan R. Epigenetic mechanisms in diabetic vascular complications and metabolic memory: the 2020 Edwin Bierman Award Lecture. Diabetes. 2021;70(2):328-37. [DOI:10.2337/dbi20-0030]
64. Guo Z, Priefer R. Current progress in pharmacogenomics of type 2 diabetes: a systemic overview. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2021;15(5):102239. [DOI:10.1016/j.dsx.2021.102239]
65. Damanhouri ZA, Alkreathy HM, Alharbi FA, Abualhamail H, Ahmad MS. A Review of the Impact of Pharmacogenetics and Metabolomics on the Efficacy of Metformin in Type 2 Diabetes. International Journal of Medical Sciences. 2023;20(1):142. [DOI:10.7150/ijms.77206]
66. Jang EJ, Lee DH, Im S-S, Yee J, Gwak HS. Correlation between PPARG Pro12Ala polymorphism and therapeutic responses to thiazolidinediones in patients with type 2 diabetes: A meta-analysis. Pharmaceutics. 2023;15(6):1778. [DOI:10.3390/pharmaceutics15061778]
67. Letourneau LR, Greeley SA. Precision medicine: long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations. Current diabetes reports. 2019;19(8):52. [DOI:10.1007/s11892-019-1175-9]
68. Vedovato N, Salguero MV, Greeley SAW, Yu CH, Philipson LH, Ashcroft FM. A loss-of-function mutation in KCNJ11 causing sulfonylurea-sensitive diabetes in early adult life. Diabetologia. 2024;67(5):940-51. [DOI:10.1007/s00125-024-06103-w]
69. Saiz-Rodríguez M, Ochoa D, Zubiaur P, Navares-Gómez M, Román M, Camargo-Mamani P,et al. Identification of transporter polymorphisms influencing metformin pharmacokinetics in healthy volunteers. Journal of Personalized Medicine. 2023;13(3):489. [DOI:10.3390/jpm13030489]
70. Serino M, Chabo C, Burcelin R. Intestinal MicrobiOMICS to define health and disease in human and mice. Current pharmaceutical biotechnology. 2012;13(5):746-58. [DOI:10.2174/138920112799857567]
71. Shukla SK, Murali NS, Brilliant MH. Personalized medicine going precise: from genomics to microbiomics. Trends in molecular medicine. 2015;21(8):461-2. [DOI:10.1016/j.molmed.2015.06.002]
72. Markowiak-Kopeć P, Śliżewska K. The effect of probiotics on the production of short-chain fatty acids by human intestinal microbiome. Nutrients. 2020;12(4):1107. [DOI:10.3390/nu12041107]
73. Fusco W, Lorenzo MB, Cintoni M, Porcari S, Rinninella E, Kaitsas F, et al. Short-chain fatty-acid-producing bacteria: key components of the human gut microbiota. Nutrients. 2023;15(9):2211. [DOI:10.3390/nu15092211]
74. Kimura I, Inoue D, Hirano K, Tsujimoto G. The SCFA receptor GPR43 and energy metabolism. Frontiers in endocrinology. 2014;5:85. [DOI:10.3389/fendo.2014.00085]
75. Ikeda T, Nishida A, Yamano M, Kimura I. Short-chain fatty acid receptors and gut microbiota as therapeutic targets in metabolic, immune, and neurological diseases. Pharmacology & therapeutics. 2022;239:108273. [DOI:10.1016/j.pharmthera.2022.108273]
76. Brown EM, Kenny DJ, Xavier RJ. Gut microbiota regulation of T cells during inflammation and autoimmunity. Annual review of immunology. 2019;37(1):599-624. [DOI:10.1146/annurev-immunol-042718-041841]
77. Dicks LM. Gut bacteria and neurotransmitters. Microorganisms. 2022;10(9):1838. [DOI:10.3390/microorganisms10091838]
78. Magne F, Gotteland M, Gauthier L, Zazueta A, Pesoa S, Navarrete P, et al. The firmicutes/bacteroidetes ratio: a relevant marker of gut dysbiosis in obese patients? Nutrients. 2020;12(5):1474. [DOI:10.3390/nu12051474]
79. Ratiner K, Ciocan D, Abdeen SK, Elinav E. Utilization of the microbiome in personalized medicine. Nature Reviews Microbiology. 2024;22(5):291-308. [DOI:10.1038/s41579-023-00998-9]
80. Pearson E. Personalized medicine in diabetes: the role of 'omics' and biomarkers. Diabetic Medicine. 2016;33(6):712-7. [DOI:10.1111/dme.13075]
81. Nair ATN, Wesolowska-Andersen A, Brorsson C, Rajendrakumar AL, Hapca S, Gan S, et al. Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes. Nature Medicine. 2022;28(5):982-8. [DOI:10.1038/s41591-022-01790-7]
82. Ilan Y. Next-generation personalized medicine: implementation of variability patterns for overcoming drug resistance in chronic diseases. Journal of Personalized Medicine. 2022;12(8):1303. [DOI:10.3390/jpm12081303]
83. Santaló J, Berdasco M. Ethical implications of epigenetics in the era of personalized medicine. Clinical epigenetics. 2022;14(1):44. [DOI:10.1186/s13148-022-01263-1]
84. Wang S, Yong H, He X-D. Multi-omics: Opportunities for research on mechanism of type 2 diabetes mellitus. World journal of diabetes. 2021;12(7):1070. [DOI:10.4239/wjd.v12.i7.1070]
85. Tobias DK, Merino J, Ahmad A, Aiken C, Benham JL, Bodhini D, et al. Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine. Nature medicine. 2023;29(10):2438-57. [DOI:10.1038/s41591-023-02502-5]
86. Non AL. Social epigenomics: are we at an impasse?. Epigenomics. 2021;13(21):1747-59. [DOI:10.2217/epi-2020-0136]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
